StockWatch
·

LORDS CHLORO ALKALI LTD. Q2 FY27 Results

LORDSCHLOQ2 FY27 Results
Filing
Result:Weak· Market: Down#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue115.408.5%17.4%
Total Income115.518.4%14.6%
Expenditure103.7314.9%19.7%
PBT11.7827.7%16.6%
Net Profit9.0239.7%0.3%
OPM16.21%5.05pp2.77pp
NPM7.80%6.23pp1.17pp
EPS3.1539.7%12.3%
View full financials

Chemicals sector core metric is adjusted PAT/margin trend: revenue grew 17.3% but PBT fell 16.6% YoY on raw-material cost pressure and margin compression (OPM 16.2% vs 18.98%), with flat PAT only propped up by a lower tax rate, so this is a below-par, deteriorating-quality print.

LORDS CHLORO ALKALI LTD. · Q2 FY2027 · THE VERDICT

Revenue at record highs masks profit collapse as caustic realizations hit worst quarter in long time

Highest quarterly revenue ever at ₹115.4 Cr, but net profit crashed 40% QoQ to ₹9.0 Cr as caustic soda realizations collapsed. Cost inflation in raw materials and employee benefits overwhelmed renewable energy savings.

11 Nov 2026 · 6 min read
Q2 Revenue

₹115.4 Cr

Highest ever; +17.3% YoY, +8.5% QoQ

Q2 Net Profit

₹9.0 Cr

Flat YoY; down 39.7% QoQ from ~₹15 Cr Q1

Net Profit Margin

7.8%

vs 9.0% in Q2 FY26; margin compression 120 bps

Lords Chloro posted its highest quarterly revenue but profit imploded. The paradox cuts through the noise: caustic soda volumes grew 9% YoY to 23,000 tons, yet net profit flatlined year-over-year and crashed 40% from the prior quarter. Management's own phrase—"worst quarter in terms of caustic soda realizations in a very long time"—is the quarter in a single sentence. Despite holding market share and volume, prices fell so steeply that margin compression overwhelmed every operational gain.

Where the profit went

Three cost headwinds collided. Raw materials surged ₹6 Cr (paraffin oil inflation tied to US-Iran geopolitical tensions; sulfuric acid spikes from the same cause). Employee benefits jumped ₹8 Cr due to Diwali bonus and half-yearly incentive payouts—management frames this as non-recurring and says the baseline will reset to 4% going forward. That's ₹14 Cr in fresh cost. The renewable energy program—21 MW solar commissioned on schedule in Q2—saved ₹5 Cr in power costs, reducing exposure from ₹8.3 per unit on the grid to ₹2 per unit on renewable. The arithmetic is brutal: ₹14 Cr in inflation minus ₹5 Cr in savings = a net ₹9 Cr profit hit, explaining the 40% QoQ collapse from ~₹15 Cr in Q1 to ₹9 Cr in Q2.

The worst quarter in terms of caustic soda realizations in a very long time. So even though there were lower product realizations, we've managed to give similar numbers.
Q1→Q2 profit bridge (₹ Cr)
-10.76-1.258.2517.7615Q1 PAT-6Raw materials-8Incentives5Power savings-3Caustic realization decline6Other net9Q2 PAT
Renewable energy offset by commodity inflation and caustic realization collapse. The newer CPW (chlorinated paraffin wax) product benefited from higher paraffin pricing but volumes still immature.
Management claims vs. what the data confirms

Highest revenue achieved, ₹115.4 Cr vs ₹100 Cr in Q2 FY26

Supported ✓

Q2 FY27 ₹115.4 Cr; YoY growth +17.3%. Confirmed.

Caustic volumes 23,000 tons, up 9% YoY vs Q2 FY26 21,000 tons

Supported ✓

23,000 ÷ 21,000 = 9.5% growth. Exact match to claimed 9% range.

Power cost savings ₹5 Cr QoQ from 21 MW solar commissioned mid-June

Supported ✓

Power & fuel ₹37.79 Cr Q2 vs ₹42.79 Cr implied Q1. Delta ≈ ₹5 Cr. Now 47 MW total operational (40% of consumption).

Caustic realizations improved to negative 1,000–0 in Alwar region

Contradicted ✗

Management acknowledged caustic worst quarter in long time; realizations down QoQ significantly despite same volumes.

What changed on this call

Caustic outlook reset. Prior guidance (FY26 calls) promised "positive momentum in caustic soda realizations driven by strong domestic demand and global commodity trends." Reality: worst quarter in a long time. This is a hard 180-degree reversal of tone. Renewable energy on schedule; target raised. 21 MW solar hit the mid-June FY26 target. Now 47 MW DC total operational covers 40% of consumption at ₹2/unit (vs grid ₹8.3, group captive ₹4.50). Management raised the long-term horizon to 70–80% renewable by 2025–26, contingent on Rajasthan policy allowing 25% contract procurement. CPW emerges as diversification bright spot. Chlorinated paraffin wax volumes surged 40% and now represent 40% of total production (100+ tons flakes, 150 tons open market, 100 tons captive use). At only 1.5 years into commercialization, the product has pricing power: paraffin oil cost inflation actually lifted CPW realizations. Company targets CPW and specialty chemicals at 20–25% of income by year 5. First specific FY27 full-year guidance. Revenue target ₹550 Cr (assumes 9 months of new 360T electrolyzer post-July 2026 commissioning). Quarterly EBITDA ₹15–20 Cr post-July. Capex ₹315 Cr total (₹150 done, ₹165 by July). Free cash flow ₹80+ Cr annually post-capex. These are quantified, narrow-band commitments—a step change from prior directional guidance.

Bull-bear ledger

  • Bull: Volume growth amid market headwinds. Caustic +9%, CPW +40% YoY. Gaining share in flat-to-down market.

  • Bull: Renewable energy execution proven. 47 MW live on schedule, now 40% of consumption. Cost ₹2/unit is a durable advantage.

  • Bull: New 360T plant (July 2026) capex on track. Incremental EBITDA ₹15–20 Cr/quarter at mid-point is ₹60+ Cr annualized.

  • Bull: Diversification pipeline emerging. CPW scaling faster than expected; specialty chemical R&D via external partner. Reduces commodity beta longer-term.

  • Bear: Caustic margin collapse to worst in long time. One-quarter data point, but severe.

  • Bear: Large-cap competition entering. Reliance scaling 6M→8M tons caustic, Adani ~10M tons. Supply glut will suppress pricing for years.

  • Bear: Cost inflation likely to persist. Paraffin oil and sulfuric acid tied to geopolitical risk (US-Iran). War premium could linger 12+ months.

  • Bear: Specialty diversification unproven. CPW is 1.5 years old. Future specialties at R&D stage. Execution risk is real.

  • Bear: Margin compression is structural, not cyclical. PAT flat YoY on 17% revenue growth. NPM fell 120 bps YoY.

Risks ranked by holder impact

Caustic realizations don't recover (supply glut from Reliance/Adani entry)

High

New capacity (Reliance 6→8M, Adani ~10M tons) floods Indian market in 2025–2026. Supply glut could keep prices depressed for 2–3 years. Lords Chloro's freight premium (Alwar region ₹36–37K vs Gujarat ₹32–33K) is real but won't offset 10M+ ton glut.

Paraffin oil cost inflation persists (US-Iran tensions)

High

Raw materials up ₹6 Cr this quarter. If geopolitical friction lingers, commodity inflation stays. CPW margin range (0–20% depending on input costs) remains volatile. Profitability stays compressed.

New plant capex execution delays past July 2026

Medium

₹165 Cr remaining capex due by July to commission 360T electrolyzer. Any slip pushes revenue and EBITDA into FY28. FY27 ₹550 Cr target misses; management credibility erodes.

Specialty chemical diversification fails to scale

Medium

Company targets 20–25% of income from CPW and unnamed specialty products by year 5. If CPW margins compress or future specialties don't gain traction, commodity exposure remains the driver. The diversification thesis is the bull case.

Rajasthan renewable energy policy change

Medium

70–80% renewable target depends on Rajasthan permitting 25% contract procurement. Policy revert stalls renewable roadmap. Cost advantage (₹2 vs ₹8.3 grid) limited to current 47 MW rather than covering majority of consumption.

How the street is positioned

The market rejected the quarter. The stock fell 4.7% on day 1 post-result and continued sliding to -5.06% by day 3, signalling the market's verdict: profit miss trumps record revenue. Stock now trades ₹129.99, down 46.3% from its all-time high of ₹241.99 and below its 20-day (₹134.75), 50-day (₹137.34), and 200-day (₹137.03) moving averages. RSI sits neutral at 43.5. Valuation is punitive: a 46% drawdown from ATH on an earnings miss (PAT -40% QoQ) leaves no near-term re-rating catalyst visible. Ownership is heavily concentrated: promoter 74.97% (stable quarter-over-quarter), FII 0.01%, DII 0.07%. Institutional absence is stark—this is a family-run, promoter-controlled business with minimal institutional penetration. No bulk or block trades suggest insider selling near the highs; the drawdown appears to reflect general market sentiment on commodity exposure, not founder de-risking. For a holder, this ownership mix means limited downside from forced institutional selling but also limited upside from new flows if the stock re-accelerates. The stock is orphaned, waiting for proof of execution.

What to watch next
  • 1 · Q3 caustic realization trend

    Management guided that caustic hit a cyclical trough (worst quarter in long time). If Q3 stabilizes or marginal recovery, bears weaken. Further deterioration reprices for multi-year commodity down-cycle.

  • 2 · July 2026 plant commissioning and EBITDA trajectory

    Proof point on capex execution. Commissioning in July and post-July quarterly EBITDA ₹15–20 Cr validates guidance and unlocks market re-rating for FY28 upside.

  • 3 · CPW margin stabilization and specialty M&A signals

    CPW margins volatile (0–20% range) with paraffin swings. Stabilization to steady 10–15% range de-risks diversification thesis. Any named specialty chemical partnership or acquisition signals serious execution intent.

This quarter marks a reset, not a reckoning. Highest revenue ever, but profit down 40% QoQ. The company executed operationally (volume, renewable energy) but was swamped by commodity and cost headwinds. The market has rightly punished it (down 46% from ATH, -5% post-result), and fundamentals don't yet justify a bounce. But the long-term thesis lives: a capable operator building renewable cost advantage and emerging diversification. Neither has proven transformational. The number to track from here is quarterly PAT post-July. If management delivers on the ₹15–20 Cr quarterly EBITDA guidance once capex concludes, PAT should stabilize in the ₹11–14 Cr range, ending the margin deterioration story. That's the inflection point. Until then, the verdict stands: **Hold**.

Informational and educational content only. Not investment advice.